Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tinengotinib Combined With Novel Endocrine Therapy in mCRPC
NCT07871110Phase 2Recruiting
- Sponsor
- TransThera Biosciences
- Start
- Sep 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tinengotinib in prostate cancer (PCa) (7 arms), sponsored by TransThera Biosciences. Primary endpoints: Safety evaluation parameters at 1 year, 6-month Progression-Free Survival rate and 1 more. Started Sep 2026; status: recruiting.
02
Drugs
tinengotinib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07871110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07871110.